Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma

2004 ◽  
Vol 91 (2) ◽  
pp. 242-247 ◽  
Author(s):  
A. J. Hayes ◽  
A. Mostyn-Jones ◽  
M. U. Koban ◽  
R. A'Hern ◽  
P. Burton ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Tumour Marker ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Shenglong Li
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Tyrosine Kinase ◽  
Malignant Tumors ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Solid Malignant Tumors

Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas, each of which is notably heterogeneous and manifested by remarkable phenotypic and morphological variability. Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) targeting c-kit, platelet-derived growth factor receptors, fibroblast growth factor receptor, and vascular endothelial growth factor receptor. In comparison with the placebo, anlotinib was associated with better overall survival and progression-free survival (PFS) in a phase III trial of patients with advanced non-small cell lung cancer (NSCLC), albeit with cancer progression after two previous lines of treatment. Recently, the National Medical Products Administration approved anlotinib monotherapy as a third-line treatment for patients with advanced NSCLC. Additionally, a phase IIB randomized trial substantiated that anlotinib is associated with a significant longer median PFS in patients with advanced soft tissue sarcoma. Moreover, anlotinib is also effective in patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma. Anlotinib has similar tolerability to other TKIs targeting vascular endothelial growth factor receptors and other tyrosine kinase-mediated pathways. However, anlotinib has a notably lower rate of side effects ≥grade 3 relative to sunitinib. This review discussed the remarkable characteristics and major dilemmas of anlotinib as a targeted therapy for sarcomas.

scholarly journals Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance

2006 ◽  
Vol 66 (17) ◽  
pp. 8770-8778 ◽  
Author(s):  
Lianglin Zhang ◽  
Jonathan A.F. Hannay ◽  
Juehui Liu ◽  
Parimal Das ◽  
Maocheng Zhan ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Tumor Growth ◽  
Vascular Endothelial ◽  
Sarcoma Cells ◽  
Endothelial Growth Factor

scholarly journals Fluorescence-guided visualization of soft tissue sarcomas by targeting vascular endothelial growth factor-A: a phase 1 single-center clinical trial

2020 ◽  
pp. jnumed.120.245696
Author(s):  
Pieter Jan Steinkamp ◽  
Bobby Klaas Pranger ◽  
Meifang Li ◽  
Matthijs D Linssen ◽  
Floris Jan Voskuil ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Soft Tissue ◽  
Phase 1 ◽  
Soft Tissue Sarcomas ◽  
Vascular Endothelial ◽  
Single Center ◽  
Endothelial Growth Factor

scholarly journals Expression of Vascular Endothelial Growth Factor and Its Receptor flk-1 in Soft Tissue Sarcomas: Correlation to Cathepsin Expression and Prognosis.

1998 ◽  
Vol 31 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Peter Würl ◽  
Helge Taubert ◽  
Axel Meye ◽  
Dieter Berger ◽  
Christine Lautenschläger ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Vascular Endothelial Growth Factor Expression and Microvascular Density in Soft Tissue Sarcomas in Dogs

2010 ◽  
Vol 22 (1) ◽  
pp. 105-108 ◽  
Author(s):  
Genilson Fernandes de Queiroz ◽  
Maria Lucia Zaidan Dagli ◽  
Heidge Fukumasu ◽  
Arturo Alejandro Zavala Zavala ◽  
Julia Maria Matera
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Microvascular Density ◽  
Vascular Endothelial ◽  
Factor Expression ◽  
Growth Factor Expression ◽  
Endothelial Growth Factor

scholarly journals Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study

2012 ◽  
Vol 36 (11) ◽  
pp. 2315-2321 ◽  
Author(s):  
Shishir Rastogi ◽  
Ramakant Kumar ◽  
Sukesh Rao Sankineani ◽  
Kanniraj Marimuthu ◽  
Laxman Rijal ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prospective Study ◽  
Tumour Marker ◽  
Vascular Endothelial ◽  
A Prospective Study ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document